A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma

Andreas Engert, Volker Diehl, Roland Schnell, Andrea Radszuhn, Maria Theresia Hatwig, Silke Drillich, Gisela Schön, Heribert Bohlen, Hans Tesch, Martin Leo Hansmann, Stefan Barth, John Schindler, Victor Ghetie, Jonathan Uhr, Ellen Vitetta

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

The anti-CD25 immunotoxin (IT), RFT5-SMPT-dgA, was used in a phase I dose escalation trial in patients with refractory Hodgkin's lymphoma. The IT was constructed by linking the monoclonal antibody RFT5 via a sterically hindered disulfide linker to deglycosylated ricin-A. All patients in this trial were heavily pretreated with a mean of 5 (range, 2 to 8) different prior therapies, including autologous bone marrow transplantation in 8 of 15. The mean age was 29 years (range, 19 to 34 years). Thirteen of 15 patients had advanced disease (stage IV) with massive tumor burdens and 6 of 15 had B symptoms. The IT was administered intravenously over 4 hours on days 1, 3, 5, and 7 for total doses per cycle of 5, 10, 15, or 20 mg/m2. Patients received one to four cycles of treatment. The peak serum concentration of intact IT varied from 0.2 to 9.7 μg/mL. The serum half life (T(1/2)) of the IT ranged from 4.0 to 10.5 hours (mean, 6.1 hours). Side effects were related to vascular leak syndrome (VLS), ie, decreases in serum albumin, edema, weight gain, hypotension, tachycardia, myalgia, and weakness. Two patients had a National Cancer Institute (NCI) grade 2 allergic reaction with generalized urticaria and mild bronchospasm. At 15 mg/m2, 1 patient experienced a grade 3 myalgia. All 3 patients receiving 20 mg/m2 experienced NCI grade 3 toxicities (edema, nausea, dyspnea or tachycardia) and 1 patient had NCI grade 4 myalgia. Thus, the maximal tolerated dose was 15 mg/m2. Seven of 15 patients made human antiricin antibodies (≤1.0 μg/mL) and 6 of 15 developed human antimouse antibodies (≤1.0 μg/mL). Clinical response included 2 partial remissions, 1 minor response, 3 stable diseases, and 9 progressive diseases. As has been predicted from the preclinical tests, these data seem to indicate clinical effecicacy of this new IT in heavily pretreated Hodgkin's patients, thus warranting further clinical investigation.

Original languageEnglish (US)
Pages (from-to)403-410
Number of pages8
JournalBlood
Volume89
Issue number2
StatePublished - Jan 15 1997

Fingerprint

Ricin
Immunotoxins
Hodgkin Disease
Refractory materials
National Cancer Institute (U.S.)
Myalgia
Antibodies
Tachycardia
Serum Albumin
Disulfides
Toxicity
Tumors
Edema
Bone
Monoclonal Antibodies
RFT5-SMPT-dgA immunotoxin
Bronchial Spasm
Maximum Tolerated Dose
Autologous Transplantation
Urticaria

ASJC Scopus subject areas

  • Hematology

Cite this

Engert, A., Diehl, V., Schnell, R., Radszuhn, A., Hatwig, M. T., Drillich, S., ... Vitetta, E. (1997). A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma. Blood, 89(2), 403-410.

A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma. / Engert, Andreas; Diehl, Volker; Schnell, Roland; Radszuhn, Andrea; Hatwig, Maria Theresia; Drillich, Silke; Schön, Gisela; Bohlen, Heribert; Tesch, Hans; Hansmann, Martin Leo; Barth, Stefan; Schindler, John; Ghetie, Victor; Uhr, Jonathan; Vitetta, Ellen.

In: Blood, Vol. 89, No. 2, 15.01.1997, p. 403-410.

Research output: Contribution to journalArticle

Engert, A, Diehl, V, Schnell, R, Radszuhn, A, Hatwig, MT, Drillich, S, Schön, G, Bohlen, H, Tesch, H, Hansmann, ML, Barth, S, Schindler, J, Ghetie, V, Uhr, J & Vitetta, E 1997, 'A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma', Blood, vol. 89, no. 2, pp. 403-410.
Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma. Blood. 1997 Jan 15;89(2):403-410.
Engert, Andreas ; Diehl, Volker ; Schnell, Roland ; Radszuhn, Andrea ; Hatwig, Maria Theresia ; Drillich, Silke ; Schön, Gisela ; Bohlen, Heribert ; Tesch, Hans ; Hansmann, Martin Leo ; Barth, Stefan ; Schindler, John ; Ghetie, Victor ; Uhr, Jonathan ; Vitetta, Ellen. / A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma. In: Blood. 1997 ; Vol. 89, No. 2. pp. 403-410.
@article{de8800087d5e48979e650b6e46f74eb3,
title = "A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma",
abstract = "The anti-CD25 immunotoxin (IT), RFT5-SMPT-dgA, was used in a phase I dose escalation trial in patients with refractory Hodgkin's lymphoma. The IT was constructed by linking the monoclonal antibody RFT5 via a sterically hindered disulfide linker to deglycosylated ricin-A. All patients in this trial were heavily pretreated with a mean of 5 (range, 2 to 8) different prior therapies, including autologous bone marrow transplantation in 8 of 15. The mean age was 29 years (range, 19 to 34 years). Thirteen of 15 patients had advanced disease (stage IV) with massive tumor burdens and 6 of 15 had B symptoms. The IT was administered intravenously over 4 hours on days 1, 3, 5, and 7 for total doses per cycle of 5, 10, 15, or 20 mg/m2. Patients received one to four cycles of treatment. The peak serum concentration of intact IT varied from 0.2 to 9.7 μg/mL. The serum half life (T(1/2)) of the IT ranged from 4.0 to 10.5 hours (mean, 6.1 hours). Side effects were related to vascular leak syndrome (VLS), ie, decreases in serum albumin, edema, weight gain, hypotension, tachycardia, myalgia, and weakness. Two patients had a National Cancer Institute (NCI) grade 2 allergic reaction with generalized urticaria and mild bronchospasm. At 15 mg/m2, 1 patient experienced a grade 3 myalgia. All 3 patients receiving 20 mg/m2 experienced NCI grade 3 toxicities (edema, nausea, dyspnea or tachycardia) and 1 patient had NCI grade 4 myalgia. Thus, the maximal tolerated dose was 15 mg/m2. Seven of 15 patients made human antiricin antibodies (≤1.0 μg/mL) and 6 of 15 developed human antimouse antibodies (≤1.0 μg/mL). Clinical response included 2 partial remissions, 1 minor response, 3 stable diseases, and 9 progressive diseases. As has been predicted from the preclinical tests, these data seem to indicate clinical effecicacy of this new IT in heavily pretreated Hodgkin's patients, thus warranting further clinical investigation.",
author = "Andreas Engert and Volker Diehl and Roland Schnell and Andrea Radszuhn and Hatwig, {Maria Theresia} and Silke Drillich and Gisela Sch{\"o}n and Heribert Bohlen and Hans Tesch and Hansmann, {Martin Leo} and Stefan Barth and John Schindler and Victor Ghetie and Jonathan Uhr and Ellen Vitetta",
year = "1997",
month = "1",
day = "15",
language = "English (US)",
volume = "89",
pages = "403--410",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma

AU - Engert, Andreas

AU - Diehl, Volker

AU - Schnell, Roland

AU - Radszuhn, Andrea

AU - Hatwig, Maria Theresia

AU - Drillich, Silke

AU - Schön, Gisela

AU - Bohlen, Heribert

AU - Tesch, Hans

AU - Hansmann, Martin Leo

AU - Barth, Stefan

AU - Schindler, John

AU - Ghetie, Victor

AU - Uhr, Jonathan

AU - Vitetta, Ellen

PY - 1997/1/15

Y1 - 1997/1/15

N2 - The anti-CD25 immunotoxin (IT), RFT5-SMPT-dgA, was used in a phase I dose escalation trial in patients with refractory Hodgkin's lymphoma. The IT was constructed by linking the monoclonal antibody RFT5 via a sterically hindered disulfide linker to deglycosylated ricin-A. All patients in this trial were heavily pretreated with a mean of 5 (range, 2 to 8) different prior therapies, including autologous bone marrow transplantation in 8 of 15. The mean age was 29 years (range, 19 to 34 years). Thirteen of 15 patients had advanced disease (stage IV) with massive tumor burdens and 6 of 15 had B symptoms. The IT was administered intravenously over 4 hours on days 1, 3, 5, and 7 for total doses per cycle of 5, 10, 15, or 20 mg/m2. Patients received one to four cycles of treatment. The peak serum concentration of intact IT varied from 0.2 to 9.7 μg/mL. The serum half life (T(1/2)) of the IT ranged from 4.0 to 10.5 hours (mean, 6.1 hours). Side effects were related to vascular leak syndrome (VLS), ie, decreases in serum albumin, edema, weight gain, hypotension, tachycardia, myalgia, and weakness. Two patients had a National Cancer Institute (NCI) grade 2 allergic reaction with generalized urticaria and mild bronchospasm. At 15 mg/m2, 1 patient experienced a grade 3 myalgia. All 3 patients receiving 20 mg/m2 experienced NCI grade 3 toxicities (edema, nausea, dyspnea or tachycardia) and 1 patient had NCI grade 4 myalgia. Thus, the maximal tolerated dose was 15 mg/m2. Seven of 15 patients made human antiricin antibodies (≤1.0 μg/mL) and 6 of 15 developed human antimouse antibodies (≤1.0 μg/mL). Clinical response included 2 partial remissions, 1 minor response, 3 stable diseases, and 9 progressive diseases. As has been predicted from the preclinical tests, these data seem to indicate clinical effecicacy of this new IT in heavily pretreated Hodgkin's patients, thus warranting further clinical investigation.

AB - The anti-CD25 immunotoxin (IT), RFT5-SMPT-dgA, was used in a phase I dose escalation trial in patients with refractory Hodgkin's lymphoma. The IT was constructed by linking the monoclonal antibody RFT5 via a sterically hindered disulfide linker to deglycosylated ricin-A. All patients in this trial were heavily pretreated with a mean of 5 (range, 2 to 8) different prior therapies, including autologous bone marrow transplantation in 8 of 15. The mean age was 29 years (range, 19 to 34 years). Thirteen of 15 patients had advanced disease (stage IV) with massive tumor burdens and 6 of 15 had B symptoms. The IT was administered intravenously over 4 hours on days 1, 3, 5, and 7 for total doses per cycle of 5, 10, 15, or 20 mg/m2. Patients received one to four cycles of treatment. The peak serum concentration of intact IT varied from 0.2 to 9.7 μg/mL. The serum half life (T(1/2)) of the IT ranged from 4.0 to 10.5 hours (mean, 6.1 hours). Side effects were related to vascular leak syndrome (VLS), ie, decreases in serum albumin, edema, weight gain, hypotension, tachycardia, myalgia, and weakness. Two patients had a National Cancer Institute (NCI) grade 2 allergic reaction with generalized urticaria and mild bronchospasm. At 15 mg/m2, 1 patient experienced a grade 3 myalgia. All 3 patients receiving 20 mg/m2 experienced NCI grade 3 toxicities (edema, nausea, dyspnea or tachycardia) and 1 patient had NCI grade 4 myalgia. Thus, the maximal tolerated dose was 15 mg/m2. Seven of 15 patients made human antiricin antibodies (≤1.0 μg/mL) and 6 of 15 developed human antimouse antibodies (≤1.0 μg/mL). Clinical response included 2 partial remissions, 1 minor response, 3 stable diseases, and 9 progressive diseases. As has been predicted from the preclinical tests, these data seem to indicate clinical effecicacy of this new IT in heavily pretreated Hodgkin's patients, thus warranting further clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=0031037004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031037004&partnerID=8YFLogxK

M3 - Article

C2 - 9002941

AN - SCOPUS:0031037004

VL - 89

SP - 403

EP - 410

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -